KRBP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KRBP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-13), Kiromic BioPharma's share price is $0.95. Kiromic BioPharma's Book Value per Share for the quarter that ended in Sep. 2024 was $-6.01. Hence, Kiromic BioPharma's PB Ratio of today is .
The historical rank and industry rank for Kiromic BioPharma's PB Ratio or its related term are showing as below:
During the past 6 years, Kiromic BioPharma's highest PB Ratio was 15.28. The lowest was 0.00. And the median was 0.00.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Kiromic BioPharma was 48.60% per year. The lowest was 48.60% per year. And the median was 48.60% per year.
The historical data trend for Kiromic BioPharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiromic BioPharma Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
PB Ratio | Get a 7-Day Free Trial | - | 5.47 | 0.87 | - | - |
Kiromic BioPharma Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
PB Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Kiromic BioPharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kiromic BioPharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Kiromic BioPharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Kiromic BioPharma's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Sep. 2024) |
= | 0.95 | / | -6.008 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Kiromic BioPharma (OTCPK:KRBP) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Kiromic BioPharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Pietro Bersani | director | C/O FUEL SYSTEMS SOLUTIONS, INC., 780 THIRD AVE. 25TH FLOOR, NEW YORK NY 10017 |
Brian Hungerford | officer: CFO | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Pamela Misajon | director | 7707 FANNIN ST, SUITE 140, HOUSTON TX 77054 |
Michael Nagel | director | C/O VASCULAR SOLUTIONS INC, 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369 |
Michael Catlin | director | 7707 FANNIN ST, SUITE 140, HOUSTON TX 77054 |
Karen Reeves | director | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Francis X Tirelli | director | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Daniel Grant Clark | officer: Interim CFO | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Internati Maurizio Chiriva | director, officer: Chairman, CEO, and President | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Michael Charles Ryan | officer: Chief Technology Officer | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Ignacio Nunez | officer: See Remarks | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Jerry A. Schneider | director | ONE VISION DRIVE, NATICK MA 01760 |
Scott Dahlbeck | officer: Chief Medical Officer | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Americo Cicchetti | director | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
Gianluca Rotino | director, officer: CSIO | 7707 FANNIN, SUITE 140, HOUSTON TX 77054 |
From GuruFocus
By PurpleRose PurpleRose • 08-22-2022
By Ds*** Ds*** • 08-30-2022
By PRNewswire PRNewswire • 08-26-2022
By Business Wire Business Wire • 05-01-2023
By PRNewswire PRNewswire • 08-23-2022
By PRNewswire PRNewswire • 08-31-2022
By PurpleRose PurpleRose • 08-27-2022
By PRNewswire PRNewswire • 08-30-2022
By Business Wire Business Wire • 02-16-2023
By PRNewswire PRNewswire • 09-01-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.